Recruiting

Personalized Surgery

Sponsor:

Oregon Health and Science University

Code:

NCT05508971

Conditions

Obstructive Sleep Apnea

Down Syndrome

Eligibility Criteria

Sex: All

Age: 2 - 17

Healthy Volunteers: Not accepted

Interventions

DISE-Directed Surgery

Adenotonsillectomy

Study Details

Brief summary:

The overall objective of this randomized clinical trial is to test the effectiveness of a personalized approach to the surgical treatment of OSA in children with Down syndrome (DS).The estimated prevalence of obstructive sleep apnea (OSA) in children with DS ranges from 45-83%, compared to 1-6% in the general pediatric population. Untreated OSA in children has been associated with daytime sleepiness, cognitive or behavioral problems, and cardiovascular complications, all which are common in children with DS. Adenotonsillectomy (AT) is the first line treatment for OSA in children, however, most large studies of AT outcomes have excluded children with DS. Available evidence demonstrates that AT is far less effective in children with DS than in the general pediatric population, with 48 to 95% of children with DS having persistent OSA after AT. Medical treatments such as positive airway pressure (PAP) therapy are frequently inadequate or poorly tolerated in this population, so many children with DS and OSA remain untreated. Drug-induced sleep endoscopy (DISE) enables direct observation of the sites and patterns of obstruction during sedated sleep using a flexible endoscope passed through the nose into the pharynx. DISE was developed to guide surgical decisions in adult OSA, and in recent years has also been used to design personalized surgical interventions in children. Using this DISE Rating Scale, the investigators have demonstrated that children with DS are more prone to tongue base and supraglottic obstruction than non-DS children, suggesting the need for more personalized surgical treatments that are tailored to the common sources of obstruction in this population. Several small case series demonstrate that DISE-directed surgery can be effective in treating OSA in children with DS. However, because there have been few prospective studies and no randomized trials comparing different treatment options in this population, there remains uncertainty about whether such a personalized approach leads to superior outcomes compared to the first line AT.

It is the investigators' hypothesis that personalized DISE-directed surgery that uses existing procedures to address specific fixed and dynamic anatomic features causing obstruction in each child with DS will be superior to the current first line approach of AT. This novel approach may improve OSA outcomes and reduce the burden of unnecessary AT or secondary surgery for persistent OSA after an ineffective AT.

Conditions

Obstructive Sleep Apnea

Down Syndrome

Study ID

NCT05508971

Start date

Aug 2, 2023

Status verified date

Jul, 2026

Completion date

Jun 30, 2028

Anticipated

Primary completion date

Dec 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 2 - 17

Healthy Volunteers: Not accepted

Requirements to participate in study:

Child has a diagnosis of Down syndrome (Trisomy 21). Child has a diagnosis of moderate to severe OSA diagnosed by PSG (oAHI ≥ 5). Child age is 2.00 to 17.99 years of age. Caregiver can provide signed and dated consent and is 18 years of age or older at the time of consent.

Caregiver can speak, read, and write in English or Spanish. Caregiver is primary caretaker of the child. Child is not expecting their own child. Child is eligible for surgical treatment

Cannot participate in study if:

Child has history of previous tonsillectomy, tonsillotomy, or partial tonsillectomy.

Child has any contraindication to surgery (e.g. bleeding disorders). Child has significant cardiopulmonary comorbidity besides OSA requiring supplemental oxygen, subglottic or tracheal stenosis, tracheostomy dependence.

Caregiver is unwilling or unable to comply with study procedures. Child is or plans to have their own child.

Study Design

Enrollment

304 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Drug-Induced Sleep Endoscopy

DISE will be performed at the time of surgery under the same sedation. The decision on specific surgical approach will be made at that time based on DISE findings. Prior to intubation, patients will be sedated with either a propofol infusion or a combination of ketamine and dexmedetomidine. Once adequate sedation is achieved, endoscopy will be performed using a flexible endoscope advanced through the nose. The nasal airway will be evaluated on both sides, then the endoscope will be advanced into the pharynx. The degree of obstruction is scored on a 3-point rating scale. Participants randomized to DISE-directed surgery will undergo one or more potential procedures in a single surgery. Caregivers will be consented for all possible procedures with the understanding that only those needed based on DISE will be performed. Importantly, these procedures are all established treatments with published outcomes data.

active comparator: Adenotonsillectomy

Adenotonsillar hypertrophy is the most common risk factor for OSA in children, and adenotonsillectomy (AT) is the first line treatment. An adenotonsillectomy is an operation to remove both the adenoids and tonsils.

Interventions

DISE-Directed Surgery

Participants randomized to DISE-directed surgery will undergo one or more potential procedures in a single surgery (i.e. DISE and subsequent sleep surgery performed) concurrently under the same general anesthetic), depending on anatomic assessment.

Adenotonsillectomy

Tonsil and adenoid removal

Primary outcome measure

  • Change from Baseline Polysomnography Measures: oAHI at 6 months [ Time Frame: 6 month follow up sleep study (after surgery) ]
  • Change from Baseline Polysomnography Measures: AHI at 6 months [ Time Frame: 6 month follow up sleep study (after surgery) ]
  • Change from Baseline Polysomnography Measures: REM AHI at 6 months [ Time Frame: 6 month follow up sleep study (after surgery) ]
  • Change from Baseline Polysomnography Measures: min SpO2 at 6 months [ Time Frame: 6 month follow up sleep study (after surgery) ]
  • Change from Baseline Polysomnography Measures: desat index at 6 months [ Time Frame: 6 month follow up sleep study (after surgery) ]
  • Change from Baseline Polysomnography Measures: % Total Sleep Time with ETCO2 > 50 mmHg at 6 months [ Time Frame: 6 month follow up sleep study (after surgery) ]
  • Change from Baseline Polysomnography Measures: Max End Tidal CO2 (ETCO2) at 6 months [ Time Frame: 6 month follow up sleep study (after surgery) ]

Central Contacts and Locations

Central contacts

Locations

Colorado Children's Hospital

Recruiting

Aurora, Colorado, United States, 80045

Contacts

Principal Investigator:

Norman Friedman, MD

University of Michigan

Recruiting

Ann Arbor, Michigan, United States, 48109

Contacts

Brittany Nordhaus

nbrittan@med.umich.edu

Principal Investigator:

Erin Kirkham, MD, MPH

Oregon Health and Science University

Recruiting

Portland, Oregon, United States, 97239

Contacts

Principal Investigator:

Derek Lam, MD, MPH

UT Southwestern Medical Center

Recruiting

Dallas, Texas, United States, 75235

Contacts

Principal Investigator:

Ron Mitchell, MD

Texas Children's Hospital

Recruiting

Houston, Texas, United States, 77030

Contacts

Principal Investigator:

Nikhila Raol, MD

EVMS Medical School

Recruiting

Norfolk, Virginia, United States, 23507

Contacts

Marysha Jones

JonesMJ@evms.edu

Lucky Enugu

enugul@evms.edu

Principal Investigator:

Cristina Baldassari, MD, FAAP

More Information

Sponsor

Oregon Health and Science University

Last update posted

Jul 6, 2026

Last verified

Jul, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Oregon Health and Science University on 2026-07-06.